Keyword : NSCLC
The era of «targets» in the treatment strategy of resectable NSCLC: from ADAURA to NeoADAURA…Т. 14, №2 (54)
New opportunities in first-line therapy of unresectable EGFRm NSCLC. Overview of clinical trials FLAURA, FLAURA2, LAURAТ. 14, №2 (54)
Induction targeted therapy with tyrosine kinase inhibitors in the treatment of EGFR-positive non-small cell lung cancer. Clinical case and discussion of features of therapeutic «targeted» tumor pathomorphosisAuthors: Sukhoversha O.A. Tsyhankov K.V. Kuzhevskyi I.V. Koval S.S. Т. 13, № 2 (50)
The role of T790M mutation in first- and second-line therapy of patients with EGFR-positive non-small cell lung cancerAuthors: Storozhenko S.A. Shparyk Ya.V. Т. 13, № 1 (49)
Modern treatment approaches of patients with NSCLC and «rare» EGFR mutations and own experience in the treatment of patients with an insertion in the 20th exonТ. 12, № 3-4 (47-48)
Five-year overall survival and progression-free survival of patients with advanced NSCLC receiving pembrolizumab
T. 10, № 3-4 (39-40)
T. 10, № 3-4 (39-40)
Erlotinib (Tarceva) as first-line treatment for patients with non-small cell lung cancer with EGFR mutations: analysis of effectiveness
